Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with an investment in MinervaX
Mandate

Vinge advises Industrifonden in connection with an investment in MinervaX

December 16, 2020 Employment and Benefits Intellectual Property M&A

Vinge has advised Industrifonden in connection with its investment in MinervaX.

MinervaX has developed a vaccine against streptococcus and in connection with the financing round has procured a total of MEUR 47.4 from a syndicate consisting of Industrifonden, Sanofi Ventures, Wellington Partners and Adjuvant Capital.

Vinge’s team primarily consisted of Johan Larsson, Sara Strandberg and Stojan Arnerstål.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025